Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Aiming toWards Evidence baSed inTerpretation of Cardiac biOmarkers in patients pResenting with chest pain-the WESTCOR study: study design.

Tjora HL, Steiro OT, Langørgen J, Bjørneklett R, Nygård OK, Renstrøm R, Skadberg Ø, Bonarjee VVS, Lindahl B, Collinson P, Omland T, Vikenes K, Aakre KM.

Scand Cardiovasc J. 2019 Jul 1:1-6. doi: 10.1080/14017431.2019.1634280. [Epub ahead of print]

PMID:
31216908
2.

Prognostic Factors in Anti-Neutrophil Cytoplasmic Antibody-Associated Glomerulonephritis with Severe Glomerular Sclerosis: A National Registry-Based Cohort Study.

Bjørneklett R, Solbakken V, Bostad L, Fismen AS.

Patholog Res Int. 2018 Jun 3;2018:5653612. doi: 10.1155/2018/5653612. eCollection 2018.

3.

Prognosis and Histological Classification in Elderly Patients with ANCA-Glomerulonephritis: A Registry-Based Cohort Study.

Bjørneklett R, Bostad L, Fismen AS.

Biomed Res Int. 2018 May 31;2018:7581567. doi: 10.1155/2018/7581567. eCollection 2018.

4.
5.

Exploring sex-specific differences in the presentation and outcomes of ANCA-associated vasculitis: a nationwide registry-based cohort study.

Bjørneklett R, Solbakken V, Bostad L, Fismen AS.

Int Urol Nephrol. 2018 Jul;50(7):1311-1318. doi: 10.1007/s11255-018-1888-8. Epub 2018 May 22.

PMID:
29790004
6.

Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.

Weiner M, Bjørneklett R, Hrušková Z, Mackinnon B, Poulton CJ, Sindelar L, Mohammad AJ, Eriksson P, Gesualdo L, Geetha D, Crnogorac M, Jayne D, Hogan SL, Geddes C, Tesar V, Aasarød K, Segelmark M.

Nephrol Dial Transplant. 2019 Feb 1;34(2):301-308. doi: 10.1093/ndt/gfy106.

7.

Cancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study.

Sriskandarajah S, Bostad L, Myklebust TÅ, Møller B, Skrede S, Bjørneklett R.

Int J Nephrol. 2017;2017:6013038. doi: 10.1155/2017/6013038. Epub 2017 Dec 18.

8.

Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy.

Knoop T, Vikse BE, Mwakimonga A, Leh S, Bjørneklett R.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1841-1850. doi: 10.1093/ndt/gfx242.

PMID:
29106593
9.

Outcome in biopsy-proven Lupus nephritis: Evaluation of biopsies from the Norwegian Kidney Biopsy Registry.

Norby GE, Mjøen G, Bjørneklett R, Vikse BE, Holdaas H, Svarstad E, Aasarød K.

Lupus. 2017 Jul;26(8):881-885. doi: 10.1177/0961203316686700. Epub 2017 Jan 6.

PMID:
28059018
10.

Prognostic Value of Histologic Classification of ANCA-Associated Glomerulonephritis.

Bjørneklett R, Sriskandarajah S, Bostad L.

Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2159-2167. Epub 2016 Oct 18.

11.

Patient classification and outcome prediction in IgA nephropathy.

Diciolla M, Binetti G, Di Noia T, Pesce F, Schena FP, Vågane AM, Bjørneklett R, Suzuki H, Tomino Y, Naso D.

Comput Biol Med. 2015 Nov 1;66:278-86. doi: 10.1016/j.compbiomed.2015.09.003. Epub 2015 Sep 25.

PMID:
26453758
12.

Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients.

Pesce F, Diciolla M, Binetti G, Naso D, Ostuni VC, Di Noia T, Vågane AM, Bjørneklett R, Suzuki H, Tomino Y, Di Sciascio E, Schena FP.

Nephrol Dial Transplant. 2016 Jan;31(1):80-6. doi: 10.1093/ndt/gfv232. Epub 2015 Jun 4.

PMID:
26047632
13.

Addition of eGFR and Age Improves the Prognostic Absolute Renal Risk-Model in 1,134 Norwegian Patients with IgA Nephropathy.

Knoop T, Vågane AM, Vikse BE, Svarstad E, Magnúsdóttir BT, Leh S, Varberg Reisæter A, Bjørneklett R.

Am J Nephrol. 2015;41(3):210-9. doi: 10.1159/000381403. Epub 2015 Apr 9.

14.

Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies.

Sriskandarajah S, Aasarød K, Skrede S, Knoop T, Reisæter AV, Bjørneklett R.

Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i67-75. doi: 10.1093/ndt/gfv008. Epub 2015 Feb 17.

15.

Mortality in patients with IgA nephropathy.

Knoop T, Vikse BE, Svarstad E, Leh S, Reisæter AV, Bjørneklett R.

Am J Kidney Dis. 2013 Nov;62(5):883-90. doi: 10.1053/j.ajkd.2013.04.019. Epub 2013 Jun 21.

PMID:
23796906
16.

Long-term risk of ESRD in IgAN; validation of Japanese prognostic model in a Norwegian cohort.

Bjørneklett R, Vikse BE, Bostad L, Leivestad T, Iversen BM.

Nephrol Dial Transplant. 2012 Apr;27(4):1485-91. doi: 10.1093/ndt/gfr446. Epub 2011 Aug 5.

PMID:
21821835
17.

Pre-transplant course and risk of kidney transplant failure in IgA nephropathy patients.

Bjørneklett R, Vikse BE, Smerud HK, Bostad L, Leivestad T, Hartmann A, Iversen BM.

Clin Transplant. 2011 May-Jun;25(3):E356-65. doi: 10.1111/j.1399-0012.2011.01424.x. Epub 2011 Mar 9.

PMID:
21651619
18.

Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantation.

Midtvedt K, Bitter J, Dørje C, Bjørneklett R, Holdaas H.

Transplantation. 2009 Jun 27;87(12):1901-3. doi: 10.1097/TP.0b013e3181a991ca. No abstract available.

PMID:
19543075
19.

Long-term risk of cancer in membranous nephropathy patients.

Bjørneklett R, Vikse BE, Svarstad E, Aasarød K, Bostad L, Langmark F, Iversen BM.

Am J Kidney Dis. 2007 Sep;50(3):396-403.

PMID:
17720518

Supplemental Content

Loading ...
Support Center